Literature DB >> 19604724

Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins.

Isabelle St-Amour1, André Laroche, Renée Bazin, Réal Lemieux.   

Abstract

The mechanisms of therapeutic action of IVIg are still unclear in most autoimmune and inflammatory diseases. IVIg have been shown to bind to a variety of human proteins including BAFF, amyloid beta peptide and GM-CSF. It has been suggested that this autoreactivity could contribute to the therapeutic immunomodulatory effects of IVIg. In this work, we showed that native IgG purified from plasma under non-denaturing conditions were much less autoreactive than IVIg. However the native IgG autoreactivity with BAFF, amyloid beta peptide and GM-CSF was significantly increased by short incubation under the slightly denaturing conditions used during industrial plasma fractionation. We conclude that the relatively mild conditions used in industrial plasma fractionation are sufficiently denaturing to activate a significant amount of cryptic autoreactive plasma IgG which could be involved not only in the therapeutic immunomodulatory effects of IVIg but also in the adverse "allergic" reactions often observed in IVIg-infused patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19604724     DOI: 10.1016/j.clim.2009.06.005

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  5 in total

Review 1.  Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.

Authors:  Sudhir Paul; Stephanie Planque; Yasuhiro Nishiyama
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

2.  Response: Granulocyte/macrophage colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy persons.

Authors:  Kanji Uchida; Brenna Carey; Takuji Suzuki; Koh Nakata; Bruce Trapnell
Journal:  Blood       Date:  2010-01-14       Impact factor: 22.113

3.  Intravenous immunoglobulin modulates the expansion and cytotoxicity of CD8+ T cells.

Authors:  Patrick Trépanier; Dominique Chabot; Renée Bazin
Journal:  Immunology       Date:  2014-02       Impact factor: 7.397

Review 4.  Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective.

Authors:  Manu Shankar-Hari; Jo Spencer; William A Sewell; Kathryn M Rowan; Mervyn Singer
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

Review 5.  Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression.

Authors:  Dominic Paquin-Proulx; Johan K Sandberg
Journal:  Front Immunol       Date:  2014-12-16       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.